Dupixent
FDA Approves Dupixent for Pediatric Eosinophilic Esophagitis
The FDA approved Dupixent to treat eosinophilic esophagitis in children ages 1 year and older.
JANUARY 26, 2024
Dupixent Reduces Asthma Exacerbations in Younger Children
Young children—6 to 11 years old—saw significantly reduced exacerbations with Dupixent, according to ...
MAY 19, 2021
Dupixent Appears to Reduce Severe Asthma Exacerbations in Children
In the United States, there are approximately 75,000 children aged 6 to 11 years with uncontrolled moderate to ...
OCTOBER 14, 2020
FDA Approves First Treatment for Chronic Rhinosinusitis With Nasal Polyps
The FDA granted a new indication for Dupixent to treat adults with nasal polyps accompanied by chronic ...
JUNE 27, 2019
FDA Approves New Indication for Dupixent for Asthma
Dupilumab inhibits the overactive signaling of IL-4 and IL-13, two key proteins that contribute to the Type 2 ...
OCTOBER 20, 2018
